| Type | Public |
|---|---|
| Traded as | BSE: 506690 |
| Industry | Pharmaceutical, Drugs & Healthcare |
| Founded | 1944, Mumbai |
| Founder(s) | Mr. Amrut Mody. |
| Headquarters | Mumbai, Maharashtra[1], India |
| Area served | Worldwide |
| Key people | Dr. P A Mody, Chairman & MD[2] |
| Revenue | 697.18 crore (US$132.46 million)[3] |
| Profit | 133.93 crore (US$25.45 million)[3] |
| Employees | 4700 |
| Subsidiaries | Niche Generics, UK,[4] Unichem SA (Pty) Ltd, Unichem Farmaceutica do Brasil Ltda & Unichem Pharmaceuticals (USA), Inc.[5] |
| Website | www.unichemlabs.com |
Unichem Laboratories (BSE: 506690) is one of the India's oldest[6] and largest pharmaceutical company headquartered in Mumbai, Maharashtra, India.[7] Its plants located in Roha (Maharashtra), Goa, Baddi (Himachal Pradesh)[8] & Ghaziabad, also new plant coming up in Sikkim.[9] The company has made more than 500 product registrations across the world and more than 500 regulatory filings such as DMFs, EDMFs. It has been granted Certificate of suitability to European Pharmacopeia (CEP) by European Directorate for the Quality of Medicines and Healthcare (EDQM) for Alfuzosin Hydrochloride.[10] Company main interest in synthesis, development, manufacturing, marketing and export of bulk drugs, chemical intermediates and formulations, serving the needs of both human and veterinary health-care.[11]
In 1944, Mr. Amrut Mody founded Unichem Laboratories in Mumbai. [12] In 1962, Unichem became a public limited company and listed on BSE.